Skip to main content

Advertisement

Table 1 Effects on spermatogenesis inhibition of various progestins combined with either dihydrosterone gel (italic), testosterone patch (underlined), or testosterone in solution or in hydroalcoholic gel formulations (bold)

From: Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France

Authors Progestin Route a Dose Percutaneous androgen Dose (mg/day) Nb b <1 million/ml at 3 months (%)c
DHT gel
Guérin & Rollet 1988 [25] MPA O 20 mg/d d Andractim TM 125 10 0
Pöllänen et al. 2001 [28] LN I 75,150,300 μg/d Andractim TM 250 23 0
O 30 μg/d Andractim TM 250 7 0
T patch
Büchter et al. 1999 [29] LN O 250–500 μg/d Testoderm TM 5 11 0
Hair et al. 2001 [30] DG O 75 μg/d Andropatch TM 5 4 0
150 μg/d Andropatch TM 5 6 50
300 μg/d Andropatch TM 5 7 70
Gonzalo et al. 2002 [31] LN I 160 μg/d Testoderm TM 10 e 20 45
O 125 μg/d Testoderm TM 10 e 15 30
T solution or gel
Soufir et al. 1983 [19] MPA O 20 mg/d PA f 50–100 6 80
Soufir et al. 2011 [22] MPA O 20 mg/d PA/Testogel TM 50–125 35 80
Guérin & Rollet 1988 [25] NT O 5 mg/d Testogel TM 250 5 100
10 mg/d Testogel TM 250 5 100
Page et al. 2006 [32] DMPA IM 300 mg/3 months Testim TM 100 21 76
Ilani et al. 2012 [35] N P 8 mg/d Androgel TM 100 20 85
12 mg/d Androgel TM 100 19 85
  1. Legend
  2. aRoute of administration; bnumber of men; cpercentage of men with less than 1 million sperm/mL at 3 months of treatment; dday; e2 patches = 10 mg; f PA percutacrine androgéniqueTM, solution of 100 mg T in 10 mL of 95% alcohol
  3. DHT dihydrotestosterone, MPA medroxyprogesterone acetate, LN levonorgestrel, T testosterone, DG desogestrel, NT norethisterone, DMPA depomedroxyprogesterone acetate, N nestorone, O oral, I implant, IM intramuscular, P percutaneous